Provided by Tiger Trade Technology Pte. Ltd.

Agenus

8.24
-0.0900-1.08%
Volume:756.92K
Turnover:6.32M
Market Cap:370.97M
PE:3.30
High:8.61
Open:8.36
Low:8.08
Close:8.33
52wk High:10.31
52wk Low:2.71
Shares:45.02M
Float Shares:40.38M
Volume Ratio:0.61
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.50
EPS(LYR):-0.0034
ROE:-1278.83%
ROA:12.53%
PB:-1.86
PE(LYR):-2,426.38

Loading ...

Agenus Q1 Sales $33.700M May Not Be Comparable To $129.500M Estimate, Net Income Of $39.2M Vs. Loss of $26.4M YoY

Benzinga Earnings
·
May 11

Immuno-oncology developer Agenus' Q1 revenue rises, posts profit

Reuters
·
May 11

Press Release: Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Dow Jones
·
May 11

Agenus Q1 FY26 net income swings to $39.2 million; revenue rises to $33.7 million

Reuters
·
May 11

Agenus Q1 Revenue USD 4.6 Million

THOMSON REUTERS
·
May 11

Corrected-Agenus Q1 Revenue USD 33.7 Million (Corrects Amount)

THOMSON REUTERS
·
May 11

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+Bal Execution Across Global Access and Phase 3 Development

THOMSON REUTERS
·
May 11

Agenus Inc expected to post earnings of $2.10 a share - Earnings Preview

Reuters
·
May 08

Agenus to report first-quarter results before market open

Reuters
·
May 05

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

THOMSON REUTERS
·
May 05

Agenus to present first Phase 2 botensilimab melanoma data at ASCO 2026

Reuters
·
Apr 21

Agenus names BAP Pharma exclusive global partner for botensilimab-balstilimab access programs

Reuters
·
Apr 21

Agenus announces annual shareholder meeting webcast

Reuters
·
Apr 21

Agenus reports Phase 2 results from BOT and BAL with agenT-797

TIPRANKS
·
Apr 18

BRIEF-Agenus Reports Phase Ii Data Demonstrating Immune Reprogramming And Durable Survival With Botensilimab, Balstilimab And Agent-797 In Pd-1 Refractory Gastroesophageal Cancer

Reuters
·
Apr 18

Agenus reports Phase II data showing 77% disease control in PD-1 refractory gastroesophageal cancer

Reuters
·
Apr 18

Agenus Inc - Study Does Not Meet Primary Endpoint of Objective Response Rate

THOMSON REUTERS
·
Apr 18